Search research articles
Contact Us
Filters
Showing results (151-160 of 181) with videos related to
Page
of 19
Sort By:
The Lancet. Infectious Diseases
|
June 12, 2015
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
José R Arribas, Pierre-Marie Girard, Roland Landman, et al.
The Lancet. HIV
|
July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 12, 2009
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression
David M Moore, Ross Harris, Viviane Lima, et al.
The Lancet. HIV
|
June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Chloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Antiviral Therapy
|
September 6, 2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio, et al.
Biochemical Pharmacology
|
June 29, 2021
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy
Lorena Vigón, Paula Martínez-Román, Sara Rodríguez-Mora, et al.
Lancet (London, England)
|
April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E Sax, David Wohl, Michael T Yin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 25, 2009
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
Josep Mallolas, Daniel Podzamczer, Ana Milinkovic, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 14, 2009
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
Daniel Podzamczer, Montserrat Olmo, Jose Sanz, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 181) with videos related to
Sort By:
Page
of 19
The Lancet. Infectious Diseases
|
June 12, 2015
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
José R Arribas, Pierre-Marie Girard, Roland Landman, et al.
The Lancet. HIV
|
July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 12, 2009
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression
David M Moore, Ross Harris, Viviane Lima, et al.
The Lancet. HIV
|
June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Chloe Orkin, Edwin DeJesus, Paul E Sax, et al.
Antiviral Therapy
|
September 6, 2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio, et al.
Biochemical Pharmacology
|
June 29, 2021
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy
Lorena Vigón, Paula Martínez-Román, Sara Rodríguez-Mora, et al.
Lancet (London, England)
|
April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E Sax, David Wohl, Michael T Yin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 25, 2009
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
Josep Mallolas, Daniel Podzamczer, Ana Milinkovic, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 14, 2009
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
Daniel Podzamczer, Montserrat Olmo, Jose Sanz, et al.
Page
of 19